Loading...
Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody
The clinical benefit of monotherapy involving immune checkpoint inhibitors (ICIs) such as anti-programmed death-1 antibody (PD-1 Ab) is limited to small populations. We previously developed a telomerase-specific oncolytic adenovirus, Telomelysin (OBP-301), the safety of which was confirmed in a phas...
Na minha lista:
| Udgivet i: | Mol Ther |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Gene & Cell Therapy
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7054725/ https://ncbi.nlm.nih.gov/pubmed/31991110 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2020.01.003 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|